George Massaro net worth and biography

George Massaro Biography and Net Worth

George E. Massaro has been Director and Vice Chairman of Huron Consulting Group, Inc., a management consulting company, since May 2010. Mr. Massaro was non-Executive Chairman of the Board of Huron Consulting Group from July 2009 to May 2010, Director and Vice Chairman of Huron Consulting Group since June 2004 (Vice Chairman since March 2005), Chief Operating Officer of Huron Consulting Group, Inc. and Huron Consulting Services LLC from June 2003 until March 2005, and Managing Director of Huron Consulting Services LLC from August 2002 to May 2003. He was the Managing Partner of Arthur Andersen's New England practice from 1998 to 2002. Mr. Massaro previously served as a director of Eastern Bank Corporation, an independent mutual bank holding company in New England from 2003 through 2017. Mr. Massaro has been a director since 2003.

What is George Massaro's net worth?

The estimated net worth of George Massaro is at least $983,526.33 as of May 9th, 2022. Mr. Massaro owns 4,677 shares of Charles River Laboratories International stock worth more than $983,526 as of October 6th. This net worth estimate does not reflect any other investments that Mr. Massaro may own. Learn More about George Massaro's net worth.

How do I contact George Massaro?

The corporate mailing address for Mr. Massaro and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected] Learn More on George Massaro's contact information.

Has George Massaro been buying or selling shares of Charles River Laboratories International?

George Massaro has not been actively trading shares of Charles River Laboratories International over the course of the past ninety days. Most recently, George Massaro sold 178 shares of the business's stock in a transaction on Monday, May 9th. The shares were sold at an average price of $230.96, for a transaction totalling $41,110.88. Following the completion of the sale, the director now directly owns 4,677 shares of the company's stock, valued at $1,080,199.92. Learn More on George Massaro's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, insiders at the medical research company sold shares 6 times. They sold a total of 39,353 shares worth more than $11,877,483.08. The most recent insider tranaction occured on August, 5th when EVP Joseph W Laplume sold 200 shares worth more than $45,226.00. Insiders at Charles River Laboratories International own 1.1 % of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 8/5/2022.

George Massaro Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/9/2022Sell178$230.96$41,110.884,677View SEC Filing Icon  
8/31/2021Sell2,539$442.48$1,123,456.724,855View SEC Filing Icon  
5/11/2021Sell371$320.06$118,742.265,696View SEC Filing Icon  
5/6/2021Sell3,370$336.96$1,135,555.207,169View SEC Filing Icon  
9/14/2020Sell1,943$219.91$427,285.1311,384View SEC Filing Icon  
5/22/2020Sell941$173.40$163,169.4012,222View SEC Filing Icon  
5/15/2019Sell1,002$131.38$131,642.7611,204View SEC Filing Icon  
5/10/2019Sell3,140$134.64$422,769.6015,344View SEC Filing Icon  
6/25/2018Sell300$115.55$34,665.0014,037View SEC Filing Icon  
5/14/2018Sell1,218$107.19$130,557.4215,055View SEC Filing Icon  
7/17/2017Sell3,830$100.81$386,102.3018,731View SEC Filing Icon  
5/12/2017Sell1,130$88.30$99,779.0015,831View SEC Filing Icon  
7/1/2016Sell3,740$83.09$310,756.6018,935View SEC Filing Icon  
5/9/2016Sell985$82.17$80,937.4513,020View SEC Filing Icon  
12/17/2015Sell7,740$80.00$619,200.0013,120View SEC Filing Icon  
5/7/2015Sell1,360$70.21$95,485.60View SEC Filing Icon  
11/3/2014Sell16,710$65.00$1,086,150.00View SEC Filing Icon  
8/26/2014Sell10,440$60.00$626,400.00View SEC Filing Icon  
5/8/2014Sell1,620$52.70$85,374.0016,510View SEC Filing Icon  
1/7/2014Sell5,750$54.00$310,500.0015,410View SEC Filing Icon  
9/16/2013Sell5,958$47.38$282,290.0415,410View SEC Filing Icon  
5/10/2013Sell2,020$44.09$89,061.80View SEC Filing Icon  
See Full Table

George Massaro Buying and Selling Activity at Charles River Laboratories International

This chart shows George Massaro's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $210.29
Low: $209.35
High: $215.73

50 Day Range

MA: $211.69
Low: $182.44
High: $250.54

2 Week Range

Now: $210.29
Low: $181.36
High: $449.34


5,684 shs

Average Volume

670,126 shs

Market Capitalization

$10.70 billion

P/E Ratio


Dividend Yield